News from #ASCO26. Personalized mRNA melanoma vaccine shows durable benefit at 5 years. This follows news at #AACR26 that a pancreatic cancer vaccine lowers recurrence risk at 6 years. mRNA technology looks like a winner for reducing cancer relapse.
www.cancerhealth.com/article/pers...
Adding a customized mRNA vaccine to checkpoint immunotherapy was associated with a 49% lower risk of melanoma recurrence or death.
